Navigation Links
MS Drug Tysabri Approved for Crohn's Disease
Date:1/14/2008

But the drug comes with serious risks, FDA notes

MONDAY, Jan. 14 (HealthDay News) -- Tysabri, a controversial drug used to treat multiple sclerosis, may also be used for patients with a moderate to severe form of another autoimmune illness, Crohn's disease, the U.S. Food and Drug Administration announced Monday.

But the drug also comes with a rare but serious risk of a potentially deadly brain infection, as well as other side effects, so it must be used carefully, the FDA said in a press teleconference.

"With the addition of Tysabri to the treatment options of sufferers of Crohn's disease, we make an important step in the armamentarium for treatment, but one that carries serious risks," said Dr. Joyce Korvick, deputy director of the division of gastroenterology products at the FDA's Office of New Drugs.

Crohn's is a serious, often painful, inflammatory bowel disorder that affects about 600,000 people in the United States. It can involve intestinal bleeding, diarrhea, weight loss, arthritis, skin problems, fever and anemia.

Tysabri (natalizumab), a monoclonal antibody used to treat MS, has been under a cloud of controversy for some time. The drug works by attaching itself to white blood cells called lymphocytes and preventing them from entering the brain, where they do damage that causes the disabling symptoms of MS.

But the drug has a checkered past. It first received U.S. Food and Drug Administration approval in November 2004, only to be pulled from the market three months later after several patients in clinical trials developed a rare but deadly viral infection of the brain called progressive multifocal leukoencephalopathy (PML).

In June 2006, the FDA allowed the drug to return to the market but with strict conditions. According to the new guidelines, Tysabri can only be administered by approved doctors, at infusion sites and pharmacies that register and comply with a patient-safety program called CD Touch, designed by Biogen Idec, the maker of Tysabri, and approved by the FDA.

Last August, an FDA advisory panel voted 12-3 in favor of the use of the drug for Crohn's disease during a joint meeting of the Gastrointestinal Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee.

At the time, the panel found that Tysabri could help ease the symptoms of the disease in patients who don't respond to standard therapies such as steroids or immunosuppressants.

The FDA is only approving Tysabri for Crohn's patients with moderate to severe symptoms, and this use will be subject to strict controls.

Korvick said that, besides the risk of PML, Tysabri also raises a patient's odds for hypersensitivity reactions, liver injury and severe herpes infections, especially in those on immunosuppressant therapy, so people taking immuno-suppressing drugs should not take Tysabri, Korvick said.

Crohn's patients who begin Tysabri therapy should also taper off their use of steroids, she added.

Side effects from the drug include headache, fatigue, infusion reactions, rash, and joint and limb pain.

"Because of these risks, patients, prescribers, pharmacies and infusion centers must all be enrolled in the [drug makers'] 'CD Touch' program and agree to comply with the company's strict monitoring guidelines," Korvick said. Doctors should also "evaluate Crohn's patients after three months of treatment to determine if they have improved on Tysabri. If not, then patients should be discontinued," she added.

According to the Wall Street Journal, Biogen Idec earlier this month noted that more than 21,000 patients were using Tysabri without any additional reports of PML.

More information

There's more on Crohn's disease at the U.S. National Institute of Diabetes and Digestive and Kidney Diseases.



SOURCES: U.S. Food and Drug Administration press teleconference with Joyce Korvick, M.D., M.P.H., deputy director, division of gastroenterology products, office of new drugs, Center for Drug Evaluation and Research, FDA; Wall Street Journal


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Stopping Tysabri May Worsen MS
2. Hiemstra Approved to Manufacture Medical Devices in New CER
3. RNs Statement on Death of Nataline Sarkisyan: CIGNA Should Have Listened to her Doctors and Approved the Transplant a Week Ago
4. Pennsylvania American Waters Rate Case Approved
5. PEGINTRON(TM) and REBETOL(R) Approved in European Union for Retreating Hepatitis C Patients Who Failed Previous Pegylated or Non-Pegylated Interferon Therapy
6. Barrs Generic Version of Estrostep(R) Fe Tablets Approved
7. A fresh look at existing therapies: Researchers explore ways to teach approved drugs new tricks
8. Voltaren(R) Gel Receives US Regulatory Approval as the First Approved Topical Prescription Treatment for Pain Associated with Osteoarthritis
9. Optometry-Backed Vision Care for Kids Act Approved by U.S. House
10. Video: New FDA-Approved Sun Protectant Saves Skin All Year Round
11. FDA Cracks Down on Unapproved Cough Medicines
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
MS Drug Tysabri Approved for Crohn's Disease
(Date:8/16/2017)... , ... August 16, 2017 , ... Paul Vitenas, ... Castle Connolly 2017 Top Doctor. The annual list identifies the nation’s top physicians, in ... Vitenas has made it to the top of Castle Connolly’s coveted ranking. , Castle ...
(Date:8/16/2017)... ... August 16, 2017 , ... SGNA Standards of Infection Control ... cycle, both between patient procedures and before storage, is a requisite practice crucial ... to the prevention of disease transmission and nosocomial infection as cleaning and HLD.” ...
(Date:8/16/2017)... ... August 16, 2017 , ... ... eBook, 9781498499620    ) shares that during the time of a cancer diagnosis, surgery and ... God's love, and all the many ways God shows love to those who ...
(Date:8/16/2017)... ... August 16, 2017 , ... ... an opportunity for men and women to train as hospice volunteers. Volunteers provide ... life-limiting illness. For over 30 years, the agency has trained volunteers to be ...
(Date:8/16/2017)... ... August 16, 2017 , ... Rollon Skin ... anti-aging skincare solutions, recently announced the launch of two new skincare products, Prache ... effective alternative to expensive plastic surgery or in-patient cosmetic dermatological procedures. , “Prache ...
Breaking Medicine News(10 mins):
(Date:8/2/2017)... , Aug. 2, 2017 ... Who,s Who as a Pinnacle Lifetime Professional in ... Key Account Manager at Turing Pharmaceuticals, AG. Her ... troubleshooting and relationship building.                ... more than 25 years of experience as a ...
(Date:8/1/2017)... 2017   CerSci Therapeutics , a non-opioid drug ... , has received notice from the National Institute on ... (NIH) that it has been awarded a Direct-to-Phase II ... in 2017 with an additional $1,000,000 to follow in ... application of their lead non-opioid drug candidate CT-044 to ...
(Date:7/28/2017)... July 28, 2017 Hill-Rom Holdings, Inc. ("Hill-Rom") ... third quarter ended June 30, 2017, and updated its ... For the fiscal third quarter, Hill-Rom ... $0.68 per diluted share in the prior-year period. These ... $0.39 per diluted share primarily related to the non-cash ...
Breaking Medicine Technology: